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S U M M A R Y
At present there is a profound paradox in antimicrobial use and development in Japan. A tightly held
domestic pharmaceutical market with signiﬁcant barriers to the importation and registration of foreign
agents, has spurred domestic pharmaceutical companies to develop a vast range of antimicrobials. Many
Japanese developed antimicrobials are now used globally. A negative consequence of this environment,
however, is the lack of availability of several ‘workhorse’ narrow-spectrum agents to treat patients in
Japan. Absent agents include anti-staphylococcal penicillins and until recently, intravenous
benzylpenicillin. In substitution for these unavailable agents, patients are frequently administered
broader spectrum antimicrobials. This change offers no additional beneﬁt to the patient and is
potentially contributing to treatment failure and high rates of antimicrobial resistance amongst key
bacterial pathogens in Japan. The situation in Japan illustrates the broader global challenges faced in
integrating the development of new antimicrobial agents with maintaining the supply and use of older
and less proﬁtable agents.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. The paradox of Japanese antimicrobials
A 3-year-old infant presents to a Tokyo hospital emergency
clinic with acute otitis media. The experienced physician notes the
severe pain and fever. She chooses to prescribe antimicrobial
therapy. The doctor is aware that Japanese children do not receive
protection against Haemophilus inﬂuenzae type B (Hib) through the
national vaccine schedule, Hib being a common, albeit prevent-
able, cause of otitis media and severe complications including
mastoiditis and meningitis. She is also aware that Japan has the
world’s highest rate of BLNAR (beta-lactamase-negative ampicil-
lin-resistant) H. inﬂuenzae, rendering most commonly used oral
antimicrobials ineffective in approximately 30% of such infections
in Japan.1 Fortunately, since 2009, Japan is the only country in the
world with an oral carbapenem available to combat such
infections.2 Therapy is successful.
In the neurology ward of the same hospital a patient is
diagnosed with neurosyphilis. Until August 2011, the clinician
would have been unable to follow almost universal treatment
recommendations suggesting intravenous benzylpenicillin, as this
agent was not approved for intravenous use.3 Likewise, a patient
suffering from Clostridium difﬁcile diarrhea has only had access to* Corresponding author. Tel.: +61 7 33465434; fax: +61 7 33465598.
E-mail address: benrogers@uq.edu.au (B.A. Rogers).
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http://dx.doi.org/10.1016/j.ijid.2012.08.001metronidazole for this indication since February 2012.4 Even now,
a patient diagnosed with methicillin-sensitive Staphylococcus
aureus endocarditis would not be able to receive the ‘gold
standard’ treatment of an anti-staphylococcal penicillin, as a
suitable agent is completely unavailable.
The vignettes above highlight some of the profound contrasts of
Japanese antimicrobial use and development, and the impact these
contrasts have on medical practice and ultimately on patients. In
essence, the current commercial and regulatory environment has
led to a nation of polar opposites.
On the positive side, a tightly held domestic pharmaceutical
industry with major regulatory and ﬁnancial hurdles to the
importation and use of foreign antimicrobial agents has spurred
signiﬁcant local antimicrobial drug development,5 defying the
recent global trend away from new antimicrobial development.6
Japan is the birthplace of many agents, including broad-spectrum
antimicrobials used regularly by infectious disease physicians and
other practitioners to treat critically ill patients the world over
(Table 1). These agents include the carbapenems such as
meropenem and doripenem, used to treat the emerging global
epidemic of multi-resistant organisms, including those harboring
extended-spectrum beta-lactamase enzymes.
Of less clear beneﬁt, the protection afforded to the domestic
industry has also facilitated the development of a large number of
‘domestic’ antimicrobials. Usually derivatives of existing classes,
many of these agents are not used widely in other nations (Table 1).ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Antimicrobial development and availability in Japan
Japanese developed antimicrobials with
a global market
Domestic Japanese antimicrobials
(without a major global market)
Agents difﬁcult to access in Japan
Carbapenems Carbapenems Agents with very recent approval
Meropenem, doripenem Biapenem, panipenem, tebipenem (oral) Oral metronidazole: approved for
Clostridium difﬁcile 2012
Quinolones Quinolones Intravenous benzylpenicillin: approved 2011
Levoﬂoxacin, norﬂoxacin, gatiﬂoxacin Pazuﬂoxacin, enoxacin, nadiﬂoxacin,
lomeﬂoxacin, tosuﬂoxacin, ﬂeroxacin,
garenoxacin, sitaﬂoxacin, pruliﬂoxacin
TMP–SMX: approved for Pneumocystis jiroveci
pneumonia in 2012; use for other indications is
allowed ‘‘only when other agents cannot be used’’
Other Other Agents that remain unavailable
Cefazolin Arbekacin (anti-MRSA aminoglycoside) Anti-staphylococcal penicillins, e.g. nafcillin,
oxacillin, cloxacillin, ﬂucloxacillin
Ceftaroline Intravenous metronidazole
Colistina Faropenem (oral ‘penem’ antimicrobial) Benzathine penicillin
Kanamycin Polymyxins, e.g. colistin,a polymyxin B
MRSA, methicillin-resistant Staphylococcus aureus; TMP–SMX, trimethoprim–sulfamethoxazole.
a Although colistin was developed in Japan, the agent is no longer available in this nation.
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antimicrobials, in other medical disciplines, particularly oncology,
the standards by which the efﬁcacy of ‘domestic’ agents has been
measured have been brought into question.5
This environment has a clear negative aspect, however, as
Japanese clinicians have not had access to a number of everyday
narrow-spectrum antimicrobials (Table 1). Clinicians in most other
nations use these ‘workhorse’ agents on a daily basis for a vast
range of conditions, ranging from minor to life-threatening. Local
experience in Japan shows that clinicians now substitute broad-
spectrum antimicrobial therapies for the absent narrow-spectrum
agents.7 These ‘substitutions’ offer no additional therapeutic
beneﬁt for the patient, and come with the additional risk of
potentiating antimicrobial resistance.
The evolution of this situation is illustrated by the case of the
narrow-spectrum penicillins, benzylpenicillin and cloxacillin.
Until the recent change to the regulatory approval, benzylpenicillin
was approved in Japan only for intramuscular use at a very low
dose (600 000 units every 6 h). Although discrepancies between
approved and real-life indications exist in many nations, Japanese
prescribers are reluctant to use therapies ‘off-label’ even when the
indication is based on the best clinical evidence.
This reluctance stems from the existence of two conﬂicting sets
of laws governing doctor’s pharmaceutical prescribing practices.
Clause 21 of the Japanese Medical Practitioners Law advises
doctors of their duty to prescribe appropriate drugs as required for
the clinical situation. Potentially conﬂicting this, Japan’s Pharma-
ceutical Affairs Law restricts prescribing only to agents approved
by these laws.8 Consequently, off-label use of antimicrobials (or
other agents), would potentially expose the doctor and hospital to
ﬁnancial penalties and medico-legal sanction. The health practi-
tioner may be refused reimbursement from the national health
insurance scheme for the therapy and the patient will be excluded
from coverage by the universally available compensation scheme
for medical adverse events.9
The competitive nature of the Japanese market has posed a
predicament to Japanese pharmaceutical companies regarding the
supply of older and cheaper antimicrobial agents. By way of
example, the cost of the benzylpenicillin in Japan is low (1 million
units = 213 JPY = 3 USD), rendering a costly application for
expanded indication non-viable on purely ﬁnancial terms. The
negative ﬁnancial impact could potentially be compounded if the
change in licensure led to diminished use of newer domestically
developed agents. The possibility of domestic (or foreign) third
parties establishing themselves in the market to supply low-cost
narrow-spectrum agents seems slim. In addition to the cost, it
would involve navigating of the regulatory authorities, which havebeen described as opaque in their decision-making process,
making any application a ﬁnancially risky process.5 This predica-
ment is in contrast to newer, high-cost agents such as linezolid,
tigecycline, and daptomycin, all of which have been successfully
licensed in the previous decade.
The least desirable outcome of this ﬁnancial and regulatory
environment is illustrated by the anti-staphylococcal penicillin,
cloxacillin. In 1998 the Japanese producer discontinued local
manufacture of this parenteral agent. With importation an
unrealistic option, for reasons outlined above, this crucial class
of antimicrobial was rendered effectively unavailable in the nation.
The only remaining agent is an infrequently utilized co-formula-
tion of cloxacillin and ampicillin, licensed at a very low dose
(cloxacillin total dose = 2000 mg/day).10 Clinicians now rely
primarily on cephalosporins, at times even using fourth-genera-
tion cephalosporins, carbapenems, or ﬂuoroquinolones when
treating susceptible staphylococcal infections. Many of these
substitute antimicrobials have neither been formally studied nor
have ‘time-tested’ experience in this indication.
The heavy use of broad-spectrum agents is one of the likely
contributors to the high rates of antimicrobial resistance in
particular organisms in Japan. Whilst such agents are invaluable in
empiric therapy and the treatment of resistant infection, their
indiscriminate use increases the risk of emergence of resistance via
‘collateral damage’.11 The ﬁrst ever description of a mobile
metallo-beta-lactamase (MBL) enzyme (blaIMP-1), originated from
Japan during the 1980s.12 These MBLs confer resistance to vitally
important carbapenem antimicrobials and remain endemic in
Japan today.13,14 The authors of the original description directly
attributed the emergence of this enzyme to the heavy use of
carbapenem agents in Japan.12
In addition, as noted earlier, there is also extreme resistance in
H. inﬂuenzae to beta-lactams,1 a phenomenon potentiated by
antimicrobial overuse and poor access to the Hib vaccine.
Regulation and licensing of vaccines in Japan remains in a similar
bind to that outlined herein for antimicrobials. A complex political
and regulatory environment has limited the availability and
uptake of a number of vaccines that are routine in almost all other
nations. Vaccines affording protection for bacterial pathogens
including Hib and Streptococcus pneumoniae are classiﬁed as
‘elective’ rather than ‘scheduled’. The consequence of this second
tier classiﬁcation is that there is no speciﬁc inclusion in national
vaccination schedules, nor any obligation for public funding of
these agents. The mechanism by which vaccines are classiﬁed into
these tiers has been described as ‘not fully transparent’ and is
discussed further in the reference provided.15 The current lay of the
land also demonstrates high rates of antimicrobial resistance in
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resistant S. aureus16 and some of the world’s highest rates of
macrolide resistance in respiratory pathogens including S.
pneumoniae and Mycoplasma pneumoniae.17
The licensing of intravenous benzylpenicillin is an encouraging
step for a number of reasons. Firstly, it represents the use of an
alternative pathway to expanded licensing indications in Japan.
Since 2010 Japanese medical specialist societies have been able to
directly apply for licensing of new agents or indications,
circumventing some of the issues highlighted above. If similar
approval has previously been granted in other nations (USA, UK,
France, or Germany), then approval may be granted in Japan
without further domestic trials. Furthermore, in addition to
licensing, the regulator may request and incentivize a supplier
in the local market to produce or import the drug if supply is not
readily available.8
Secondly, this process was initiated by IDATEN, Japan’s nascent
community of infectious disease specialists.18 By global standards
this community is small. Despite an otherwise highly developed
medical workforce, Infectious Disease has not traditionally been a
recognized specialty. Few hospitals in Japan have access to a
trained Infectious Diseases specialist, let alone a department with
other roles including antimicrobial management and stewardship,
now emerging as the standard of care in other nations.19 The
expanded licensing of benzylpenicillin (and other antimicrobials)
highlights what may be a major task for this society in the future.
There are now generations of clinicians in Japan who have little
experience treating patients with such traditional and narrow-
spectrum agents. These clinicians will require considerable
encouragement, education, and support in order to begin utilizing
them to their full potential.
Like many other nations and the global community as a whole,
Japan faces signiﬁcant challenges balancing antimicrobial devel-
opment and use. The ﬁrst difﬁculty lies in uncoupling the supply
and use of off-patent and commercially unproﬁtable narrow-
spectrum antimicrobials from purely commercial imperatives that
may lead to their demise.20 The second challenge is in creating an
environment that fosters the continued development of new
antimicrobial agents, although not by simply encouraging their
overuse in order to provide a ﬁnancial return. We hope that the
recent expanded licensing of intravenous benzylpenicillin, and
other agents, prompted by the emergence of a new voice from the
infectious disease community in Japan, is a ﬁrst step in rebalancing
the nation’s formulary. Enhancing Japanese clinicians’ access to
important narrow-spectrum antimicrobials will greatly beneﬁt
patients in Japan. Continued good work by the Japanese
pharmaceutical industry in the development of new antimicrobial
agents beneﬁts the global community as a whole.
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